Diagnosis and follow-up of patients with congenital hypothyroidism detected by neonatal screening

Amparo Rodríguez Sánchez, María J. Chueca Guindulain, María Alija Merillas, Susana Ares Segura, José Carlos Moreno Navarro, María Dolores Rodríguez Arnao, in representation of the Grup de Trabajo de Tiroides of the Sociedad Española de Endocrinología Pediátrica (SEEPI)

KEYWORDS
Congenital hypothyroidism; Neonatal screening; Early detection; Follow-up units for endocrine diseases; Free T4; TSH; L-thyroxin; Molecular genetics

Abstract
The screening programme of congenital hypothyroidism (CH) is probably one of the best achievements in paediatrics. Thyroid hormones are essential for brain development and brain maturation that continue through the neonatal period. Hypothyroidism that begins in the first months of life causes irreversible damage to the central nervous system, and is one of the most frequent and preventable causes of mental retardation. As children with congenital hypothyroidism are born with a normal appearance, analytical studies are required to immediately start the appropriate therapy.

This article analyses the aims, diagnostic procedures, tests required, aetiology, and differential diagnosis in this disorder. Especially relevant is to perform frequent monitoring to ensure dose adjustments of L-Thyroxine therapy, avoiding infra- or supra-dosing that negatively affects neurosensory functions. Re-evaluation of the aetiology permanent vs transient hypothyroidism is always recommended after 3 years of chronological age.
Objective of the neonatal screening programme for congenital hypothyroidism

The Programme for the Early Detection of Congenital Hypothyroidism, a public health and preventive medicine priority, is part of the neonatal screening programme.

Its main goal is the detection and treatment of severe and permanent CHT. Detection of mild permanent CHT or transient CHT is a secondary objective of screening.

In all of these forms of CHT, early detection prevents neurologic damage and reduces the morbidity, mortality and potential disabilities associated with the disease.

It is important to emphasise that neonatal screening tests are not diagnostic procedures. Patients with a positive result of screening require additional diagnostic evaluation, which requires the support of clinicians specialised in the diagnosis and treatment of the disease (clinical follow-up centres [CFUCs]). Clinical follow-up centres should meet certain conditions (Tables 1 and 2). Their purpose is to confirm or rule out the diagnosis of CHT, and promptly initiate treatment if applicable.8,9

Neonatal screening should not be understood as a mere laboratory procedure, but as a multidisciplinary activity whose coordination with the health care system is essential to ensure its effectiveness and efficiency.

Procedure for neonatal screening for congenital hypothyroidism

Measurement of TSH

The collection of samples is scheduled so that coverage of 100% of newborns is ensured, along with treatment of 100% of the detected cases.

Screening for early detection of primary congenital hypothyroidism is performed by measurement of the levels of TSH at 48 h post birth to avoid the initial physiological elevation of this hormone after birth.
A capillary blood sample is obtained from the ewborn by heel puncture and collected on standard filter paper; this procedure needs to be performed by specially trained healthcare staff to optimise yield.9

The serum levels of TSH are measured by immunofluorescence assay (DELFIA™, Laboratorios Perkinelmer). The cut-off point above which CHT is suspected has been established at 7–10 IU/mL. When the TSH value exceeds the established threshold, the total thyroxine level (tT4) is measured as well.

At present, all centres that screen for CHT in Spain measure the levels of TSH, while the levels of both TSH and tT4 are only measured simultaneously in the initial test in a few autonomous communities (Basque Country, Navarre and Cantabria).

Central hypothyroidism (secondary or tertiary) is not detected by screening programmes that only measure TSH.10,11

Confirmation of congenital hypothyroidism

In case of a positive screen result, the facility that did the screening urgently contacts the patient for referral to the corresponding CFUC, where testing will be performed for confirmation of hypothyroidism and to establish the aetiology of the abnormal thyroid function, without delaying initiation of treatment.12-17

The aetiology of congenital hypothyroidism is multifactorial. In 95% of cases the patient has primary hypothyroidism (abnormalities in the thyroid gland), while central hypothyroidism is less frequent.

Congenital and neonatal hypothyroidism are present from birth. Depending on the aetiology, the hypothyroidism may be permanent and require lifelong treatment, or it may be transient and resolve spontaneously when the underlying cause disappears (e.g. excessive concentration of iodine or the presence of maternal antithyroid antibodies). Notwithstanding, every patient requires treatment to normalise thyroid function during the period of brain development, and treatment is inefficient if it starts later (existence of a "window of opportunity").

The most frequent cause of primary CHT is thyroid dysgenesis (85%–90%), in most cases thyroid ectopia (60%–65%), followed by thyroid agenesis or athyreosis (35%–40%). Different forms of thyroid dysmorphogenesis (Table 3) account for 10% of cases. Specific mutations in the transcription termination factor 2 gene (TTF2) and genes encoding other thyroid transcription factors have been identified in some patients with thyroid dysgenesis.

In some cases, the aetiology of hypothyroidism cannot be determined. Numerous genes may be involved in the multifactorial aetiology of primary congenital hypothyroidism.17-24

---

### Table 1 Objectives of clinical follow-up centres for congenital hypothyroidism.

<table>
<thead>
<tr>
<th>Objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirming the CHT diagnosis through history-taking, physical examination and the necessary diagnostic tests (blood and imaging tests) with immediate turnaround of results.</td>
</tr>
<tr>
<td>Informing and reassuring the family; explaining the benefits of early detection</td>
</tr>
<tr>
<td>Urgent initiation of treatment (levothyroxine) with optimisation of treatment during follow-up visits until thyroid function normalises</td>
</tr>
<tr>
<td>Achieving a normal neurologic and psychomotor development and an intellectual quotient within the normal range while preventing comorbidities</td>
</tr>
<tr>
<td>Diagnosing the aetiology (permanent vs transient CHT)</td>
</tr>
<tr>
<td>Diagnosing other potentially associated congenital anomalies</td>
</tr>
<tr>
<td>Ongoing bidirectional information sharing with the diagnosing facility to assess the outcomes and effectiveness of the programme</td>
</tr>
<tr>
<td>Establishing a direct relationship with the patient’s paediatrician to coordinate care</td>
</tr>
</tbody>
</table>

Sources: Rodríguez-Arnao et al.8 and Rodríguez Sánchez et al.15.

### Table 2 Requirements for clinical follow-up centres for congenital hypothyroidism.

<table>
<thead>
<tr>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paediatric endocrinologists with experience in CHT and full-time dedication</td>
</tr>
<tr>
<td>Department of Biochemistry with rapid testing capabilities for diagnostic confirmation and follow-up evaluation</td>
</tr>
<tr>
<td>Department of Nuclear Medicine (initial urgent thyroid scintigraphy)</td>
</tr>
<tr>
<td>Department of Paediatric Radiology (thyroid ultrasound, bone age study)</td>
</tr>
<tr>
<td>Department of Psychology for evaluation</td>
</tr>
<tr>
<td>Inpatient and neonatal care services</td>
</tr>
<tr>
<td>Relationship with the patient’s paediatrician</td>
</tr>
<tr>
<td>Direct communication with the diagnosing institution to assess the outcomes and efficacy of the programme</td>
</tr>
<tr>
<td>Periodic communication with the Subdirección General de Salud Pública and the Department of Health or the institution overseeing the programme</td>
</tr>
<tr>
<td>Expert Committee meetings to assess and improve programme outcomes</td>
</tr>
</tbody>
</table>

Fuente: Rodríguez-Arnao et al.8 and Rodríguez Sánchez et al.15.
Table 3  Aetiology of congenital hypothyroidism. Thyroid dyshormonogenesis.

<table>
<thead>
<tr>
<th>Defects in iodine trapping or transport</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Mutation in thyroid peroxidase gene</td>
</tr>
<tr>
<td>2. Defects in organification</td>
</tr>
<tr>
<td>3. Defective iodotyrosine coupling</td>
</tr>
<tr>
<td>4. Iodotyrosine dehalogenase deficiency</td>
</tr>
<tr>
<td>5. Abnormal iodoproteins</td>
</tr>
<tr>
<td>6. Abnormalities in thyroglobulin synthesis</td>
</tr>
<tr>
<td>7. Insensitivity to TSH</td>
</tr>
</tbody>
</table>

Table 4  Clinical signs and symptoms of congenital hypothyroidism. Congenital hypothyroidism index.

Points given per sign or symptom | A | B |
---|---|---|
1. Female sex | 0.3 | 1 |
2. Gestation >40 weeks | 0.3 | 1 |
3. Prolonged jaundice | 0.3 | 1 |
4. Weight >3500 g | 0.5 | 1 |
5. Umbilical hernia | 1 | 2 |
6. Poor sucking | 1 | – |
7. Hypotonia | 1 | 1 |
8. Constipation | 1 | 2 |
9. Macroglossia | 1 | 1 |
10. Inactivity | 1 | – |
11. Mottled skin | 1 | 1 |
12. Dry and rough skin | 1.5 | 1 |
13. Posterior fontanelle > 0.5 mm² | 1.5 | 1 |
14. Classic facies | 3 | 2 |

Clinical score suggestive of congenital hypothyroidism: >4 points.
Source: Letarte A. et al., 1980.12

Diagnostic tests. The results of the dried blood spot test are confirmed by venous blood tests (TSH, free thyroxine [FT4]). In primary hypothyroidism, elevated TSH levels are associated with reduced levels of FT4. Thyroglobulin levels are measured to assess for the presence of the thyroid gland. The presence of antithyroid antibodies supports the diagnosis of transient autoimmune thyroditis due to hormone blocking. Elevation of iodine levels in the urine (>200 μg/L) suggests excessive exposure to iodine with blocking of thyro receptors.

Imaging tests, such as thyroid ultrasound and scintigraphy, are very useful in determining the aetiology of CHT. They allow the definitive diagnosis of dysgenesis, while detection of an eutopic thyroid gland with normal tracer uptake may suggest transient CHT.

A thyroid ultrasound examination can verify the presence of thyroid tissue in the neck. It can differentiate between thyroid dysgenesis (agenesis or ectopia) and dyshormonogenesis, which manifests with presence of the thyroid gland in the normal location. However, the interpretation of thyroid ultrasound findings in the newborn requires a high degree of specialisation.

Thyroid scintigraphy with sodium iodide I 131 or technetium Tc 99m can be used to determine the position and size of the thyroid gland and establish a definitive diagnosis of thyroid agenesis, ectopia, haimagenesis or hypoplasia. If the thyroid cannot be visualised with scintigraphy in a patient with elevated thyroglobulin levels, it may be helpful to perform an ultrasound scan, as this may be due to the presence of thyroid-blocking antibodies (maternal autoimmune thyroid disease), a defect in iodide trapping in cases of dyshormonogenesis (NIS mutation), a genetic change in the TSH-β gene or inactivating mutations of the TSH receptor gene. In cases of partial block of thyroid hormonogenesis, the thyroid may be eutopic and of normal size.

Other tests (not essential to the initial diagnosis).

Auditory evoked potentials: the relationship between hypothyroidism and hearing loss is well established. Some
forms of thyroid dysshormogenesis (Pendred syndrome, Hollander syndrome) should be suspected if there is a family history of hearing loss.

Congenital malformations may be more frequent in patients with CHT compared to the general population, especially congenital heart defects, and therefore, performance of a cardiology evaluation is recommended in these patients. An evaluation by a paediatric neurologist at the time of diagnosis is also very useful to detect potential comorbidities associated with psychomotor retardation.

**Definitive diagnosis of congenital hypothyroidism**

The treatment of children identified through screening programmes for early detection of CHT must be maintained without interruption through age 3 years to ensure normal thyroid function until brain growth is complete, whether the hypothyroidism is transient or permanent. At age 3 years, patients without a definitive diagnosis may undergo re-evaluation (Fig. 2).

Children with an initial diagnosis of thyroid agenesis or ectopic thyroid, which are both permanent, do not require re-evaluation. The diagnosis ought to be re-evaluated in children with CHT and a normally positioned thyroid at the time of initial diagnosis, and in children with CHT of unknown aetiology. Re-evaluation should also be contemplated in patients in whom the diagnosis was not confirmed (by scintigraphy) at the time treatment was initiated. There are 2 possible approaches to the diagnostic re-evaluation, which should always be performed after the patient reaches age 3 years.

To determine whether the hypothyroidism is permanent or transient, it is sufficient to halve the current dose of levothyroxine and measure the levels of TSH and FT4 one month after: if the TSH level is 10mIU/L or higher, the hypothyroidism is considered permanent and the patient will resume treatment with levothyroxine at the dose that achieved normal thyroid function. In patients with a very high initial level of TSH and an eutopic thyroid gland, discontinuing levothyroxine for just 2 weeks should be enough to produce elevation of TSH.

If the aim is to make a definitive diagnosis, treatment with levothyroxine should be suspended for 1 month, followed by measurement of levels of FT4, TSH, thyroglobulin and antithyroid antibodies (antithyroglobulin or anti-thyroid peroxidase). If it was not performed before initiation of treatment, thyroid scintigraphy with technetium 99 can be used to diagnose an ectopic thyroid or possibly thyroid agenesis, which would be confirmed with a thyroid ultrasound scan. In patients with permanent CHT with eutopic thyroid gland, thyroid scintigraphy with sodium iodide I 131 allows performance of a perchlorate discharge test for assessment.

---

### Table 5 Special situations in the early detection of congenital hypothyroidism.

<table>
<thead>
<tr>
<th>Newborns with gestational age ≤30 weeks</th>
<th>Birth weight ≤1500 g</th>
<th>Use of iodine antiseptic products during delivery or in the care of the newborn (caesarean section, major surgery)</th>
<th>Performance of radiologic tests with iodinated contrast media</th>
<th>Silastic catheter insertion, cardiac catheterization</th>
<th>Down syndrome</th>
<th>Multiple birth, especially twins of the same sex (potential for foeto-foetal transfusion syndrome)</th>
<th>Newborns admitted to intensive care unit</th>
<th>Post-transfusion samples</th>
</tr>
</thead>
</table>

*Source: Rodriguez Sánchez et al.*

---

**Treatment of congenital hypothyroidism**

In congenital and neonatal hypothyroidism, the degree of brain damage is directly associated with the time elapsed between onset of hypothyroidism and initiation of treatment. Thus, treatment should be initiated as soon as possible, preferably before age 15 days. Treatment should start the day the diagnosis is made, and its initiation should not be delayed pending performance of additional diagnostic tests.

The first-line drug is synthetic levothyroxine via the oral route, administered 30 min before a feeding once every 24 h at a dose of 10–15 μg/kg/day. Liquid compounded formulations of levothyroxine are not stable. The absorption of levothyroxine is hindered by ingestion of foods or products containing soy, iron, calcium, aluminium hydroxide, omeprazole, fibre, sucralfate or bile acid sequestrants.

Once treatment with levothyroxine starts, the patient must undergo frequent clinical and laboratory follow-up evaluations to optimise treatment. We recommend a second visit 2 days after diagnosis to confirm acceptance of the diagnosis and prescribed treatment, a third evaluation at 15 days with measurement of TSH and FT4 levels, then monthly visits in the first 6 months of life, followed by visits every 2 months until age 1 year, and visits every 3–4 months until the patient is re-evaluated at age 3 years.

Each follow-up visit should include a full physical examination and measurement of FT4 and TSH levels. The aim of treatment is to quickly normalise FT4 and TSH levels. Free thyroxine levels must remain in the upper range of normal to avoid subclinical hypo- and hyperthyroidism. The levels of TSH and FT4 must be measured 4 weeks after any dosage change.
of dyshormonogenesis. Molecular genetic testing is very useful in the diagnosis of CHT.

The following findings are suggestive of permanent CHT in patients with an eutopic thyroid gland: history of goitre or primary congenital hypothyroidism with eutopic thyroid gland in first-degree relative, thyroid hypoplasia at the time of initial diagnosis, need for high doses of levothyroxine (>2 μg/kg/day) during the follow-up, thyroid hyperplasia at the time of re-evaluation.

Table 3 summarises the aetiological classification of CHT based on the results of the diagnostic re-evaluation. If a permanent aetiology is confirmed, the family needs to be informed of the need to maintain treatment with levothyroxine for life with the required dose adjustments. In case of transient hypothyroidism, treatment is discontinued.

Prognosis
Early detection of CHT through neonatal screening prevents the intellectual disability formerly observed in these children when the diagnosis was clinical and delayed. Patients with CHT that receive early and adequate treatment have normal intellectual quotients.17,18,36,38,39

In some cases, mild brain impairment occurs despite early initiation of treatment, resulting in behavioural problems, and impairment in language comprehension, fine motor skills and visual-perceptual motor skills, usually with little impact on the ability to carry out a normal life. These abnormalities have been associated with the age at initiation of treatment (greater than 15–21 days), the dose of levothyroxine (usually lower than recommended), the initial severity of hypothyroidism and fT4 levels below or above the recommended range during the follow-up. Excessive levels of fT4 in the early months of life may be associated to inattention in subsequent years.35

Discontinuation of treatment before age 3 years without medical supervision or subsequent follow-up can have dire effects on neurologic development.

Follow-up in these patients is important not only to achieve healthy maturation, but also optimal growth and development. In countries where there are no CFUCs for patients with CHT, the reported proportion of patients that discontinue treatment prematurely ranges between 25% and 30%.37,40

Transition to adult care
Children with CHT should be followed up in a CFUC through puberty and until reaching their final height.16,17 Thereon, follow-up visits should be scheduled every 6–12 months, or more frequently in case of poor adherence. The purpose of followup is to monitor thyroid function to prevent subclinical hypo- or hyperthyroidism and the associated cardiovascular problems, excess weight and bone mineralisation defects in adulthood.

Only 70% of adults with CHT adhere to treatment correctly. This is particularly alarming in the case of women who are or wish to become pregnant, whose thyroid hormone requirements are greater. Optimal treatment of maternal hypothyroidism is essential to achieve a normal pregnancy with healthy neurocognitive development in the child. Monitoring of treatment is recommended throughout childhood and adulthood. Educational strategies need to be developed and implemented to improve adherence to treatment, especially during the transition to adult care.

Unresolved problems in the early detection of congenital hypothyroidism
Even if the results of screening are normal, if there is clinical suspicion of hypothyroidism the paediatrician should request urgent measurement of serum FT4 and TSH levels, as the elevation of TSH may occur later in some patients. Other infrequent causes, such as consumptive hypothyroidism in the postnatal period secondary to overexpression of type 3 deiodinase in patients with large haemangiomas, will not be detected in screening tests due to normal levels of TSH and T4 in the early stages.27

The screening protocol that measures TSH alone cannot identify cases of central CHT.10,11 The incidence of central CHT, whether isolated or associated with hypopituitarism, is higher (1 per 16,000 to 20,000 live births) than previously reported (1 per 100,000), so expanded screening with simultaneous measurement of TSH and tT4 levels is recommended. For now, we advocate for measurement of T4 levels in the newborn screening sample, as this would
prevent delayed diagnosis in these patients, in many of whom symptoms may be either absent or nonspecific.

Abnormalities in TSH-α and TSH-β may manifest with a late elevation of TSH. Changes in the monocarboxylate transporter 8 (MCT8) gene should be suspected in patients with neurologic manifestations in the first year of life and initially manifest with normal thyroid function.¹⁶,¹⁷

Conclusions

The Programme for the Early Detection of CHT constitutes one of the greatest advances in child health and preventive medicine of the XX century. The identification of these patients prevents the suffering involved in living with permanent brain damage in both the individual and the family. From an economic perspective, these programmes offer a high yield to society, yet only 25% of the global population benefits from them.

Further cost-benefit analyses are required to establish a consensus regarding the need to measure the levels of only TSH, only T4 or both to allow detection of central hypothyroidism too, and whether the cut-off point for TSH should be lowered to 5 mIU/L to allow detection of milder forms of hypothyroidism while avoiding an increase in the false-positive rate.

For all the above reasons, in upcoming years the necessary infrastructure should be developed to provide these programmes with the capability to apply current scientific knowledge, and their positive outcomes disseminated effectively in health care and social forums.

Conflicts of interest

The authors have no conflicts of interest to declare.

Appendix 1. Members of the Thyroid Working Group of the Sociedad Española de Endocrinología Pediátrica (Spanish Society of Paediatric Endocrinology)

Calmari Jaume, Maria, Hospital Universitario Son Espases, Balearic Islands; Casano Sancho, Paula Hospital Sant Joan de Déu, Barcelona; Grau Bolado, Gema, Hospital Cruces, Bizkaia; Muñoz Calvo, M. Teresa, Hospital Infantil Niño Jesús, Madrid; Rial Rodriguez, José Manuel, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, and Temboury Molina, Carmen, Hospital del Sureste, Madrid.

Appendix B. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.anpede.2018.11.011.

References